Fibrosis markers in hepatitis C

摘要: Significant morbidity and mortality due to chronic hepatitis C infection have led efforts identify patients at risk of progressive disease. Current clinical practice relies on liver biopsy as the gold standard for assessing severity C, but is associated with sampling error exposes procedural risks additional health care expenses. Several surrogate markers fibrosis now been developed, although they validated only in select patient populations do not accurately differentiate between intermediate stages fibrosis. Additional studies determine utility noninvasive are progress.